LEVADEX Analysis Shows Potential to Treat a Broad Spectrum of Migraine ***UPDATED SATELLITE COORDINATES***
Migraine is a common, debilitating neurological disorder that affects approximately 30 million people in the United States, according to the National Headache Foundation. Limitations of oral triptans, the class of prescription drugs widely used for migraines, include slow onset of significant pain relief between 45 and 90 minutes, substantial variability in patient response and side effects such as heightened blood pressure.
MAP Pharmaceuticals, Inc. will present analysis of data from the efficacy portion of the first Phase 3 trial of LEVADEX(TM) at the 14th Congress of the International Headache Society. Data from this Phase 3 trial show the potential of LEVADEX to be effective in treating acute migraine as well as a broad spectrum of migraine, including migraine subpopulations that are often resistant to current therapies, migraine with moderate and severe pain, migraine with nausea and vomiting, and migraine with and without aura. LEVADEX is an orally inhaled migraine therapy that patients administer themselves using the company's proprietary TEMPO(R) inhaler.
SATELLITE FEED: Thursday, September 10th, 2009 2:00 PM - 2:15 PM ET Galaxy 19 C-Band Transponder 10 Downlink Freq. 3900 Horizontal
NEWS: New Data Presented at the International Headache Society's Annual Congress Suggests New, Investigational Migraine Treatment Could Help Provide Relief for 30 Million Sufferers in the U.S.
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/40023/consumer.html
SOUNDBITES: * Dr. Stephen Silberstein, Director of the Headache Center, Jefferson University Hospitals * Migraine patient B-ROLL INCLUDES: * Dr/Patient footage * MAP corporate headquarters - exteriors and lab footage * manufacturing footage * product shots
VIDEO PROVIDED BY: MAP Pharmaceuticals, Inc.
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3
|SOURCE MAP Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved